Search
01/02/2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Thaci, D, Strober, B, Gordon, KB, Foley, P, Gooderham, M, Morita, A, Papp, KA, Puig, L, Menter, MA, Colombo, MJ, Elbez, Y, Kisa, RM, Ye, JN, Napoli, AA, Wei, L, Banerjee, S, Merola, JF, Gottlieb, AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2)DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3.400(Q2/3D).
01/01/2022
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Armstrong, AW, Soliman, AM, Betts, KA, Wang, Y, Gao, YW, Stakias, V, Puig, L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1)DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3.400(Q2/3D).
01/01/2022
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
Krueger, J, Puig, L, Thaci, D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7.300(Q1/1D).
01/01/2022
Pathophysiology of Generalized Pustular Psoriasis
Marrakchi, S, Puig, L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7.300(Q1/1D).